Metabolism
Serine/threonine kinase AMPK upregulates glucose uptake by promoting the expression and function of glucose transporters. AMPK is activated by increased AMP/ATP ratio, resulting from cellular and environmental stress, e.g. low glucose, heat shock, hypoxia and ischemia. AMPK activation positively modulates signaling transductions that refill ATP levels. Moreover, it also stimulates catabolic processes such as fatty acid oxidation and glycolysis through inhibition of ACC and activation of PFK2. AMPK negatively regulates various proteins which are important to ATP-consuming mechanisms, e.g. mTORC2, glycogen synthase, SREBP-1, and TSC2, causing the downregulation/inhibition of gluconeogenesis and glycogen, lipid and protein synthesis.
- A4063 MPC-3100Summary: Hsp90 inhibitor
- A4064 NVP-BEP800Target: HSP90Summary: Oral Hsp90β inhibitor, novel, fully synthetic
- A4065 PF-04929113 (SNX-5422)Target: HSP90Summary: Hsp90 inhibitor,potent and selective
- A4067 RadicicolSummary: ATPase/kinase inhibitor
- A4068 SNX-21121 CitationSummary: Hsp90 inhibitor,ATP-competitve,potent and selective
- A4227 Tipifarnib (Zarnestra)Summary: Farnesyltransferase inhibitor,potent and specific
- A8202 Abiraterone acetateTarget: Cytochrome P450 (CYP450)Summary: Cytochrome p450 17a1 inhibitor
- A4240 Abiraterone1 CitationSummary: Potent CYP17 inhibitor
- A4300 GW96621 CitationSummary: PPARγ antagonist
- A4301 T0070907Summary: Human PPARγ antagonist,potent and selective